iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares REMUS REMUS PHARMACEUTICALS LIMITED INE0O5T01011 Board Meeting New 2025-05-17 Yes 2025-04-01 2025-05-19 Financial results Dividend Other business Audited Standalone And Consolidated Yearly March 2025 Final Further, in this connection, please refer our earlier intimation dated March 27, 2025, whereby, pursuant to the Company’s Code of Conduct framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended (“the Code”), the Trading Window for dealing in securities of the Company, for persons specified under the Code, was closed from April 01, 2025 till 48 hours after the Audited Standalone and Consolidated Financial Results of the Company for the half year and financial year March 31, 2025 are approved by the Board of Directors and submitted to Stock Exchange.